OncoMatch/Clinical Trials/NCT07103395
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
Is NCT07103395 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant therapy and Consolidative therapy for lung cancer (nsclc).
Treatment: Neoadjuvant therapy · Consolidative therapy — This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4), bevacizumab and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4), surufatinib and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage III
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy
Cannot have received: radiotherapy
No prior radiotherapy
Cannot have received: surgery
No prior surgery
Cannot have received: targeted therapy
No prior targeted therapy
Cannot have received: immunotherapy
No prior immunotherapy
Cannot have received: anti-PD-1 therapy
Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10⁹/l; platelets ≥ 100 × 10⁹/l; hemoglobin ≥ 9.0 g/dl
Kidney function
creatinine clearance ≥ 50 ml/min as calculated by the cockcroft-gault formula
Liver function
serum bilirubin ≤ 1.5 × upper limit of normal (uln); ast and alt ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07103395 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages